HUTCHMED· @hutchmed · X·· 28 天前精选AI 评分58
AI 导读
和黄医药宣布,其子公司与GSK就first-in-class KRAS-EGFR ATTC候选药HMPL-A830达成的独家开发与许可协议已正式完成交割。该协议此前已对外公告,本次为交割进展,授权范围为中国以外地区。
推荐理由
和黄医药与GSK就KRAS-EGFR ATTC候选药HMPL-A830的独家开发许可协议完成交割,读者可了解该交易的标的与授权范围。
正文
Further to our earlier announcement, we are pleased to share that the exclusive development and license agreement between subsidiaries of HUTCHMED and GSK for HMPL-A830, a first-in-class KRAS-EGFR ATTC candidate, has officially closed. https://www.hutch-med.com/closing-of-kras-egfr-attc-license-to-gsk-outside-china/
来源:HUTCHMED · x.com